Serum Advanced Glycation End-Products (AGEs / CML)
Heterogeneous group of irreversible adducts formed non-enzymatically between reducing sugars and protein amino groups (Maillard reaction).
Standard vs. Optimal Reference Rangesug/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<5.0 ug/mL
General reference distribution across unselected commercial populations.
<3.0 ug/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Reacts with lysine/arginine residues to form N-carboxymethyl-lysine (CML) and pentosidine, cross-linking extracellular matrix proteins.
Differential Diagnosis
Elevated Levels (AGEs / CML High)
- •Chronic hyperglycemia and poorly controlled diabetes
- •High intake of high-heat browned foods
- •End-stage renal disease
Low Levels (AGEs / CML Low)
- •Low tissue glycation burden
- •Optimal glycemic and culinary habits
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for AGEs / CML
- Targeted organ system imaging or functional dynamic testing related to protein cross-linking & glycation
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Serum Advanced Glycation End-Products - The New England Journal of Medicine (2021). PMID: 33990124
- [2]AGEs / CML Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Serum Advanced Glycation End-Products (AGEs / CML) into overall healthspan optimization.